Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.

Gidal BE, Maganti R, Laurenza A, Yang H, Verbel DA, Schuck E, Ferry J.

Epilepsy Res. 2017 Apr 26;134:41-48. doi: 10.1016/j.eplepsyres.2017.04.018. [Epub ahead of print]

PMID:
28535410
2.

Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.

Wong H, Bohnert T, Damian-Iordache V, Gibson C, Hsu CP, Krishnatry AS, Liederer BM, Lin J, Lu Q, Mettetal JT, Mudra DR, Nijsen MJMA, Schroeder P, Schuck E, Suryawanshi S, Trapa P, Tsai A, Wang H, Wu F.

Drug Discov Today. 2017 May 2. pii: S1359-6446(17)30002-8. doi: 10.1016/j.drudis.2017.04.015. [Epub ahead of print]

PMID:
28476536
3.

Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age.

Schwarz HP, Walczak M, Birkholz-Walerzak D, Szalecki M, Nanu M, Woehling H, Schuck E.

Adv Ther. 2016 Mar;33(3):423-34. doi: 10.1007/s12325-016-0301-1. Epub 2016 Feb 17.

4.

Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study.

Arzimanoglou A, Ferreira JA, Satlin A, Mendes S, Williams B, Critchley D, Schuck E, Hussein Z, Kumar D, Dhadda S, Bibbiani F.

Eur J Paediatr Neurol. 2016 May;20(3):393-402. doi: 10.1016/j.ejpn.2015.12.015. Epub 2016 Jan 11.

5.

An integrated platform for simultaneous multi-well field potential recording and Fura-2-based calcium transient ratiometry in human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes.

Rast G, Weber J, Disch C, Schuck E, Ittrich C, Guth BD.

J Pharmacol Toxicol Methods. 2015 Sep-Oct;75:91-100. doi: 10.1016/j.vascn.2015.04.005. Epub 2015 Apr 25.

PMID:
25921432
6.

Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.

Schuck E, Bohnert T, Chakravarty A, Damian-Iordache V, Gibson C, Hsu CP, Heimbach T, Krishnatry AS, Liederer BM, Lin J, Maurer T, Mettetal JT, Mudra DR, Nijsen MJ, Raybon J, Schroeder P, Schuck V, Suryawanshi S, Su Y, Trapa P, Tsai A, Vakilynejad M, Wang S, Wong H.

AAPS J. 2015 Mar;17(2):462-73. doi: 10.1208/s12248-014-9716-2. Epub 2015 Jan 29.

7.

One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age.

Schwarz HP, Birkholz-Walerzak D, Szalecki M, Walczak M, Galesanu C, Metreveli D, Khan-Boluki J, Schuck E.

Biol Ther. 2014 Dec;4(1-2):1-13. doi: 10.1007/s13554-014-0014-4. Epub 2014 Jan 28.

8.

Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase.

Ferraris D, Duvall B, Delahanty G, Mistry B, Alt J, Rojas C, Rowbottom C, Sanders K, Schuck E, Huang KC, Redkar S, Slusher BB, Tsukamoto T.

J Med Chem. 2014 Mar 27;57(6):2582-8. doi: 10.1021/jm401856k. Epub 2014 Feb 24.

PMID:
24520856
9.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators..

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.

10.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects.

Yu Y, Logovinsky V, Schuck E, Kaplow J, Chang MK, Miyagawa T, Wong N, Ferry J.

J Clin Pharmacol. 2014 May;54(5):528-36. doi: 10.1002/jcph.249. Epub 2014 Jan 2.

PMID:
24343761
11.

Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope(®) in children requiring growth hormone treatment.

Pfäffle R, Schwab KO, Marginean O, Walczak M, Szalecki M, Schuck E, Zabransky M, Zucchini S.

Ther Adv Endocrinol Metab. 2013 Feb;4(1):3-11. doi: 10.1177/2042018813479644.

12.

Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice.

Yu Y, Desjardins C, Saxton P, Lai G, Schuck E, Wong YN.

Int J Pharm. 2013 Feb 25;443(1-2):9-16. doi: 10.1016/j.ijpharm.2013.01.010. Epub 2013 Jan 11.

PMID:
23313921
13.

Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian men.

Aikawa N, Okubo Y, Lynn M, Rossignol DP, Wong YN, Schuck E, Kitahara Y, Nakano T, Sivak O, Wasan KM, Nagy C, Yen M.

Innate Immun. 2012 Dec;18(6):793-803. doi: 10.1177/1753425912441845. Epub 2012 Mar 29.

PMID:
22459966
14.

A transcellular assay to assess the P-gp inhibition in early stage of drug development.

Taur JS, Schuck EL, Wong NY.

Drug Metab Lett. 2012;6(4):285-91.

PMID:
23879790
15.

Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.

Kumar V, Schuck EL, Pelletier RD, Farah N, Condon KB, Ye M, Rowbottom C, King BM, Zhang ZY, Saxton PL, Wong YN.

Cancer Chemother Pharmacol. 2012 Jan;69(1):229-37. doi: 10.1007/s00280-011-1687-8. Epub 2011 Jun 23.

PMID:
21698359
16.

Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.

Narayan S, Carlson EM, Cheng H, Condon K, Du H, Eckley S, Hu Y, Jiang Y, Kumar V, Lewis BM, Saxton P, Schuck E, Seletsky BM, Tendyke K, Zhang H, Zheng W, Littlefield BA, Towle MJ, Yu MJ.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1634-8. doi: 10.1016/j.bmcl.2011.01.097. Epub 2011 Jan 25.

PMID:
21324692
17.

Novel second generation analogs of eribulin. Part III: Blood-brain barrier permeability and in vivo activity in a brain tumor model.

Narayan S, Carlson EM, Cheng H, Condon K, Du H, Eckley S, Hu Y, Jiang Y, Kumar V, Lewis BM, Saxton P, Schuck E, Seletsky BM, Tendyke K, Zhang H, Zheng W, Littlefield BA, Towle MJ, Yu MJ.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1639-43. doi: 10.1016/j.bmcl.2011.01.096. Epub 2011 Jan 26.

PMID:
21324687
18.

Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells.

Taur JS, DesJardins CS, Schuck EL, Wong YN.

Xenobiotica. 2011 Apr;41(4):320-6. doi: 10.3109/00498254.2010.542256. Epub 2010 Dec 17.

PMID:
21162698
19.

Wheat-dependent exercise-induced anaphylaxis exclusively during menstruation.

Fischer J, Schuck E, Biedermann T.

Allergy. 2010 Oct;65(10):1347-8. doi: 10.1111/j.1398-9995.2010.02356.x. Epub 2010 Mar 18. No abstract available.

20.

Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study.

Gueniche A, Knaudt B, Schuck E, Volz T, Bastien P, Martin R, Röcken M, Breton L, Biedermann T.

Br J Dermatol. 2008 Dec;159(6):1357-63. doi: 10.1111/j.1365-2133.2008.08836.x. Epub 2008 Sep 15.

PMID:
18795916

Supplemental Content

Loading ...
Support Center